Arena Pharmaceutical (ARNA) FDA Briefing Documents Released
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
FDA briefing documents are now out on Arena Pharmaceuticals (Nasdaq: ARNA) related to weight loss drug Locaserin. The documents come ahead of the May 10 FDA AdCom.
In October 2011, Arena and partner Eisai Inc. received a Complete Response Letter (CRL) from the FDA on Locaserin. In December 2011, the comapny resubmitted the lorcaserin NDA and the he FDA accepted the resubmission for and assigned a PDUFA date of June 27th.
Shares of ARNA have been flying around all morning ahead of the documents.
In October 2011, Arena and partner Eisai Inc. received a Complete Response Letter (CRL) from the FDA on Locaserin. In December 2011, the comapny resubmitted the lorcaserin NDA and the he FDA accepted the resubmission for and assigned a PDUFA date of June 27th.
Shares of ARNA have been flying around all morning ahead of the documents.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Rupert Murdoch considering re-merger of Fox Corp and News Corp - Reuters
- Mark Walter's biggest insurer sees banks pause sales amid probe - Bloomberg
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
